MedTrace Logo

Phase 2, Multiple Ascending Dose Proof of Concept Study

NCT02710604 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2017-09-13

No results posted yet for this study

Summary

This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

Conditions

Interventions

DRUG

CMX157

tablet

DRUG

TDF

300mg tablet

Sponsors & Collaborators

  • ContraVir Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Sullivan-Boylai, MD · ContraVir Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-07-18
Completion
2017-07-18

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710604 on ClinicalTrials.gov